Literature DB >> 1588285

A role for complement receptor-like molecules in iron acquisition by Candida albicans.

M A Moors1, T L Stull, K J Blank, H R Buckley, D M Mosser.   

Abstract

Candida albicans, an opportunistic fungal pathogen of humans, is dependent upon iron for growth. Consequently, human serum inhibits C. albicans growth due to the presence of high affinity iron-binding proteins that sequester serum iron, making it unavailable for use by the organism. We report that in the inhibitory environment of human serum, the growth of C. albicans can be restored by the addition of exogenous hemoglobin or heme, but not by protoporphyrin IX, the heme precursor that does not contain iron. We further report that C. albicans can utilize cell surface proteins that are homologues of the mammalian complement receptors (CR) to rosette complement-coated red blood cells (RBC) and obtain RBC-derived iron for growth. The ability of Candida to acquire RBC-derived iron under these conditions is dependent upon Candida-RBC rosetting mediated by CR-like molecules. Unopsonized RBC do not support Candida growth in serum, and restoration of Candida growth in serum by complement-opsonized RBC is inhibited by monoclonal antibodies to the human CR type 3 (CR3). In addition, activation of the human alternative pathway of complement by Candida leads to "bystander" deposition of C3 fragments on the surface of autologous, unopsonized RBC, generating the ligands necessary for Candida-RBC rosetting. These results suggest that C. albicans has evolved a unique strategy for acquiring iron from the host, which exploits the host complement system, and which may contribute to the pathogenic potential of the organism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588285      PMCID: PMC2119266          DOI: 10.1084/jem.175.6.1643

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  46 in total

1.  REVERSAL OF SERUM FUNGISTASIS BY ADDITION OF IRON.

Authors:  L CAROLINE; C L TASCHDJIAN; P J KOZINN; A L SCHADE
Journal:  J Invest Dermatol       Date:  1964-06       Impact factor: 8.551

2.  Effect of Friend leukemia virus infection on susceptibility to Candida albicans.

Authors:  M A Moors; S M Jones; K K Klyczek; T J Rogers; H R Buckley; K J Blank
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

3.  Reduced expression of the functionally active complement receptor for iC3b but not for C3d on an avirulent mutant of Candida albicans.

Authors:  M W Ollert; E Wadsworth; R A Calderone
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

4.  Critical role of germ tube formation in the pathogenesis of candidal vaginitis.

Authors:  J D Sobel; G Muller; H R Buckley
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

5.  Yeast adhesion in the pathogenesis of endocarditis due to Candida albicans: studies with adherence-negative mutants.

Authors:  R A Calderone; R L Cihlar; D D Lee; K Hoberg; W M Scheld
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

6.  Pathogenicity of morphological and auxotrophic mutants of Candida albicans in experimental infections.

Authors:  M G Shepherd
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

7.  Bacteremia and fungemia in patients with neoplastic disease.

Authors:  E Whimbey; T E Kiehn; P Brannon; A Blevins; D Armstrong
Journal:  Am J Med       Date:  1987-04       Impact factor: 4.965

8.  Hydroxamate siderophore production by opportunistic and systemic fungal pathogens.

Authors:  M Holzberg; W M Artis
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

9.  Hepatocyte iron kinetics in the rat explored with an iron chelator.

Authors:  M J Pippard; D K Johnson; C A Finch
Journal:  Br J Haematol       Date:  1982-10       Impact factor: 6.998

10.  Expression of a high-affinity mechanism for acquisition of transferrin iron by Neisseria meningitidis.

Authors:  C Simonson; D Brener; I W DeVoe
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

View more
  27 in total

1.  Candida albicans specializations for iron homeostasis: from commensalism to virulence.

Authors:  Suzanne M Noble
Journal:  Curr Opin Microbiol       Date:  2013-10-10       Impact factor: 7.934

Review 2.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 3.  Cell wall and secreted proteins of Candida albicans: identification, function, and expression.

Authors:  W L Chaffin; J L López-Ribot; M Casanova; D Gozalbo; J P Martínez
Journal:  Microbiol Mol Biol Rev       Date:  1998-03       Impact factor: 11.056

Review 4.  Acquisition, transport, and storage of iron by pathogenic fungi.

Authors:  D H Howard
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

Review 5.  Complement-related proteins in pathogenic organisms.

Authors:  Z Fishelson
Journal:  Springer Semin Immunopathol       Date:  1994

6.  Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocyte-derived macrophages.

Authors:  Y Minn; E Brummer; D A Stevens
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

Review 7.  The iC3b receptor of Candida albicans and its roles in pathogenesis.

Authors:  Margaret K Hostetter
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

8.  Reduced inhibition of Candida albicans adhesion by saliva from patients receiving oral cancer therapy.

Authors:  M Umazume; E Ueta; T Osaki
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

9.  Production of a hemolytic factor by Candida albicans.

Authors:  J M Manns; D M Mosser; H R Buckley
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Ca ions stabilize the binding of complement factor iC3b to the pseudohyphal form of Candida albicans.

Authors:  L Spötl; J Möst; M P Dierich
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.